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Major advances in the past decade have led a better understanding of the pathophysiology
of narcolepsy with cataplexy (NC) caused by the early loss of hypothalamic hypocretin
neurons. Although a role for hypocretin in the regulation of sleep/wakefulness state
is widely recognized, other functions, not necessarily related to arousal, have been
identified. Hence, the hypocretin system enhances signaling in the mesolimbic pathways
regulating reward processing, emotion and mood regulation, and addiction. Although
studies on hypocretin-deficient mice have shown that hypocretin plays an essential role
in reward-seeking, depression-like behavior and addiction, results in human narcolepsy
remained subject to debate. Most of studies revealed that hypocretin-deficient narcolepsy
patients either drug-free or medicated with psychostimulant had preferences toward
risky choices in a decision-making task under ambiguity together with higher frequency of
depressive symptoms and binge eating disorder compared to controls. However, human
studies mostly reported the lack of association with pathological impulsivity and gambling,
and substance and alcohol abuse in the context of narcolepsy-cataplexy. Prospective
larger studies are required to confirm these findings in drug-free and medicated patients
with narcolepsy. Inclusion of patients with other central hypersomnias without hypocretin
deficiency will provide answer to the major question of the role of the hypocretin system
in reward-based behaviors and emotional processing in humans.
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INTRODUCTION
The orexins (orexin A and B) (Sakurai et al., 1998) or hypocretins
(hypocretin 1 and 2) (De Lecea et al., 1998) are neuropeptides
produced by several thousand neurons restricted to the lateral
hypothalamus (Peyron et al., 1998; Date et al., 1999; Nambu
et al., 1999). These neurons project widely to the olfactory bulb,
cerebral cortex, thalamus, hypothalamus and brainstem, and par-
ticularly densely to the locus coeruleus, tuberomamillary nucleus,
raphe nucleus, and bulbar reticular formation (Peyron et al.,
1998; Date et al., 1999; Nambu et al., 1999). The actions of
hypocretins are mediated via two orphan G protein-coupled
receptors, orexin-1 (OX1R) and orexine-2 (OX2R) receptors (also
known as Hcrtr-1 and Hcrtr2). In the central nervous system,
Hcrtr-1 and Hcrtr2 mRNA have different and complementary
expression patterns suggesting that these receptors have dis-
tinct physiological roles through different neuronal pathways
(Marcus et al., 2001). Hcrtr-1 mRNA was observed in the limbic
cortex but also detected in the hippocampus and in paraven-
tricular thalamic nucleus, ventromedial hypothalamic nucleus,
dorsal raphe nucleus, and locus coeruleus. In contrast, Hcrtr2
mRNA was found more diffusely in the cortex and more promi-
nent in septal nuclei, hippocampus, medial thalamic groups,
raphe nuclei, paraventricular nucleus, and ventral premammil-
lary nucleus.
Studies in basic neuroscience have largely documented the role
of hypocretin-1 and -2 in a variety of physiological processes
such as arousal and the maintenance of waking (Sutcliffe and De
Lecea, 2002; Taheri et al., 2002; Adamantidis et al., 2007) feeding
behavior and energy metabolism (Willie et al., 2001), neuroen-
docrine and autonomic function and regulation of cardiovascular
function (Samson et al., 2005). Subsequently, studies of effer-
ent and afferent projections of hypocretin neurons revealed the
implication of the hypocretin system in the mesolimbic pathways
regulating emotion, reward processing and addiction (Boutrel
et al., 2005; Harris et al., 2005).
Narcolepsy with cataplexy (NC) is a rare debilitating neuro-
logical disorder that affects approximately 0.026% of the general
population. The disease is characterized by excessive daytime
sleepiness (EDS), cataplexy (i.e., sudden weakening of muscle
tone triggered by emotions), fragmented nocturnal sleep, and
other dissociated manifestations of rapid eye movement sleep
phenomena such as sleep paralysis and hypnagogic hallucina-
tions (Dauvilliers et al., 2007). In addition, to sleep symptoms,
NC is also associated with reduced quality of life (Ervik et al.,
2006; Dodel et al., 2007; Dauvilliers et al., 2009; Vignatelli
et al., 2011), mood symptoms (Dauvilliers et al., 2009; Fortuyn
et al., 2011) and cognitive alterations (Bayard et al., 2012a).
NC is caused by an extensive loss of hypothalamic neurons
producing hypocretin (Peyron et al., 2000; Thannickal et al.,
2000). Accordingly, low/undetectable cerebrospinal hypocretin-1
is observed in almost all patients with NC (Dauvilliers et al.,
2007). The specific physiopathology of NC provides a fascinating
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insight into the roles of hypocretin in human behavioral
regulation.
In this review, we describe and discuss physiological, behav-
ioral and neuroimaging data from human NC that favors the
role of the hypocretin system in reward-based behaviors, emo-
tion regulation, decision-making processing, mood symptoms,
and addiction.
REGULATION OF SATIETY
Food intake is partially mediated through brain pathways for
motivation and reinforcement with close interaction with the
reward processing (Kelley et al., 2005; Wise, 2006). The question
of whether common brain mechanisms mediate the acquisi-
tion and development of eating and addiction habits remains
unknown. Food is a daily necessity and obesity is largely
attributed to excess caloric intake induced by excessive hedo-
nic drive even in condition with normal metabolic need (Wise,
2013). In some cases, obesity may reflect addiction to high-energy
foods with parallels to addiction behavior toward drug and alco-
hol. Recent advances have been made in identifying the metabolic
feedback signals and neural systems, located mainly in brainstem
and hypothalamus that represent a “homeostatic” energy bal-
ance regulatory system (“wanting” for food), but also the neural
pathways and functions mainly located in cortico-limbic struc-
tures referred to as “hedonic” drive of eating (“liking for food”)
(Berridge et al., 2010; Berthoud, 2011). Limbic areas such as
nucleus accumbens and ventral pallidum play a central role in the
“liking” food intake. The latter system referred to external sensory
information processing, reward processing, and cognition and
executive functions where opioid, endocannabinoid and orexin
signals modulate the sensory pleasure. Midbrain dopamine neu-
rons with projections to the nucleus accumbens in the ventral
striatum have been strongly implicated in food and drug reward
with the potential to strongly affect the amount of energy con-
sumed (Kalivas et al., 1993; Wise, 2006, 2013; D’Ardenne et al.,
2008). Dysfunction in reward circuits may thus contribute to
obesity and eating disorders with neurochemical evidence (i.e.,
alteration in dopamine or opioids) of abnormal reward-related
brain functions in animal models of binge eating, bulimia, and
anorexia nervosa (Berthoud et al., 2011; Avena and Bocarsly,
2012).
The recent discovery of orexin/hypocretin and melanin
concentrating hormone expressing neurons in the lateral
hypothalamus acted as metabolic sensors and modulated energy
homeostasis, hedonic pleasure, decision-making to make opti-
mal adaptive choices, and reward-seeking (Yoshida et al., 2006;
Berridge et al., 2010). A close interaction between the hypocre-
tinergic and dopaminergic systems in satiety control was also
supported by data showing that orexin in the posterior ventral
pallidum can enhance liking for sweets rewards as with mu opi-
oid stimulation (Ho and Berridge, 2013). NC is associated with
excessive weight gain particularly at disease onset and in children
(Okun et al., 2002) with a global increased frequency of obesity
also in adults (Dahmen et al., 2001). Interestingly, weight gain in
NC appears not related to EDS (i.e., inactivity) (Kok et al., 2003)
or higher food intake from controlled diary study (Lammers et al.,
1996). As hypocretin was primarily known to regulate feeding
behavior and metabolism (Sakurai, 2003), some studies were
recently conducted to explore eating disorders prevalence in NC.
In a small clinical sample, Chabas and colleagues reported
that patients with typical cataplexy (n = 7) had higher scores on
the Eating Attitude Test (EAT-40) and had more frequent fea-
tures of bulimia nervosa compared to controls (n = 9) (Chabas
et al., 2007). Fortuyn and colleagues showed that patients with
NC display various symptoms of eating disorders. In their case-
controlled study, 23.3% of the patients fulfilled the criteria
for a clinical eating disorder, and none in controls (Fortuyn
et al., 2008). Four patients (6.7%) had bulimia nervosa, only
one had anorexia nervosa, and nine (15%) were classified as
Eating Disorder-Not Otherwise Specified (i.e., subthreshold of
bulimia nervosa, binge eating disorder). On the symptom level,
25% of patients reported binging twice a week or more often.
Interestingly, these results were essentially the same when patients
were compared to BMI-matched controls and were note related
to medication use. Same results were obtained by Dimitrova
and colleagues who reported higher scores on the Binge Eating
Scale in patients with NC, with moderate or severe binge eating
in 23% (Dimitrova et al., 2011). Finally, a recent study aimed
at assessing the prevalence of sleep-related disorder (SRED) in
NC (Palaia et al., 2011). SRED is a non-rapid eye movement
parasomnia defined by recurrent episodes of involuntary eating
and drinking during arousals from the main sleep period. In
this cohort of 65 consecutive adult patients with NC, SRED was
significantly associated with NC (32 vs. 3% in BMI-matched con-
trols). Interestingly, SRED in NC was not associated with weight
gain suggesting a possible primary effect of hypocretin deficiency.
Finally, by examining 166 patients with NC and 80 controls with
self-report structured interview, no difference was found in the
current prevalence of eating disorders (i.e., bulimia nervosa, binge
eating disorder, or anorexia nervosa), nor was the frequency of
eating attacks higher in the narcolepsy group (Dahmen et al.,
2008).
In conclusion, even being still controversial, patients with NC
may present an increased frequency of subtle changes in eating
behavior with binge eating and compulsive sleep related-eating
disorder. However, eating disorders per se could not explain the
positive energy balance leading to frequent overweight in patients
with narcolepsy-cataplexy. In the future, it would be worthwhile
to use more precise instruments including those measuring sati-
ety after standardized meals and to measure basal metabolic rates
by indirect calorimetry. It remains also required to study the
brain reward mechanisms that generate homeostatic energy bal-
ance regulatory and hedonic drive of eating systems and their
interactions in hypocretin-deficient patients with narcolepsy-
cataplexy.
EMOTIONAL PROCESSING
Several models of emotion highlight the role of particular brain
regions in emotion identification, response and regulation that
involve cortical, subcortical and limbic (i.e., amygdala and medial
prefrontal cortex) structures. The amygdala plays a major role
in interpretation of emotionally significant stimuli, with strong
projections to the hypocretin area (Sakurai, 2005). Recent stud-
ies have explored the structural and functional integrity of the
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amygdala in human NC. One study using magnetic resonance
imaging (MRI) spectroscopy suggested amygdala involvement in
NC (Poryazova et al., 2009). As in patients with amygdala lesions,
patients with NC failed to exhibit startle potentiation during
unpleasant stimuli (Khatami et al., 2007). A psychophysiologi-
cal investigation in NC also revealed an attenuated reaction to
unpleasant pictures (Tucci et al., 2003). Recent functional MRI
studies examined brain activation patterns in patients with NC
when shown humorous material. One of these studies revealed
an enhanced ventral striatum and hypothalamus response in
patients with NC while shown humorous cartoons (Reiss et al.,
2008). In contrast, positive humorous pictures elicited reduced
hypothalamic response together with pronounced activity in
amygdala in another NC study (Schwartz et al., 2008). Recently,
the same group reported a reduced amygdala activity during
aversive conditioning together with an increased activity in the
bilateral amygdala and the dorsal striatum during positive emo-
tional stimuli in NC (Ponz et al., 2010a,b). All these find-
ings suggest an amygdala involvement in the pathophysiology
of NC, which would result in abnormal emotional processing
under both pleasant and unpleasant conditions. Very recently,
we have explored a classical emotional processing (i.e., facial
affect recognition) in patients with NC compared with patients
with central hypersomnia without cataplexy and healthy con-
trols (Bayard et al., 2012b). As most of previous studies suggested
the involvement of amygdala structure in the perception and
judgment of fear (Adolphs et al., 1994; Morris et al., 1996)
as well as happiness and sadness (Fusar-Poli et al., 2009), we
hypothesized that patients with NC would show impaired recog-
nition of these emotions in facial expressions. Furthermore, we
were also interested to study their emotional regulation strate-
gies (using a self-rated questionnaire) based on the frequent
coping behavior in NC to avoid specific emotional situations
that trigger cataplexy. We found that patients with NC did
not significantly differ from controls in their emotional judg-
ment (valence and arousal) with normal emotion recognition in
facial expressions as well as in their explicit emotional regulation
strategies.
In conclusion, neuroimaging studies provided convincing evi-
dence for a central role of the amygdala in the pathophysiology
of human NC. Observation of both exaggerated and reduced
amygdala activation remains puzzling. This observation might
probably reflect the complex interaction and synergy between
amygdala and other limbic brain regions (i.e., prefrontal cortex,
nucleus accumbens, ventral striatum) depending on the nature
of the processing elicited by the stimuli used (i.e., reward, aver-
sive conditioning or humorous pictures processing). Finally, the
normal performance on facial expression recognition observed in
NC may rely on the recruitment of alternate brain circuitries that
exclude the amygdala pathway. An alternate hypothesis is that the
metabolic changes inconstantly reported in the amygdala struc-
ture in NC (Poryazova et al., 2009) are not sufficient to alter the
emotion recognition signaled by facial expressions. An overlap
between the emotional and the social brain may thus be empha-
sized with promising perspective to identify new pathophysiologi-
cal pathways in studying emotion in hypocretin-deficient patients
with narcolepsy.
DECISION-MAKING PROCESSING
Hypocretin system is implicated in reward processing and addic-
tion by sending direct and indirect projections to dopaminergic
regions i.e., the ventral tegmental area, the nucleus accumbens,
and the amygdala (Sakurai, 2007; Aston-Jones et al., 2009).
Given that subjects with altered feedback sensitivity showed
decision-making problems, and that impulsive decision-making
was a condition of intolerance to delay-of-reward, several stud-
ies were interested in assessing decision-making and impulsivity
in pathologies associated with dopamine system abnormalities
or dopaminergic medication. Hence, poor decision-making per-
formances and impulsivity were reported in psychiatric (e.g.,
drug dependence and pathological gambling) and neurological
pathologies (Parkinson’s disease and restless legs syndrome), all
disorders being characterized by an abnormal reward-mediated
processing involving the dopaminergic system (Dunn et al., 2006;
Bayard et al., 2010; Kertzman et al., 2011; Fond et al., 2012).
In neuropsychological research, decision-making is commonly
assessed with laboratory tasks such as the Iowa gambling task
(IGT) (Bechara et al., 2000), the game of dice task (GDT)
(Brand et al., 2005), or the Balloon Analog Risk Task (BART)
(Lejuez et al., 2002). The IGT is based on reinforcement learn-
ing, which measures the ability to balance short-term rewards
against long-term losses where premises, outcomes, rewards, or
punishments are initially uncertain (decision under ambiguity).
In contrast, in the GDT, the potential consequences of differ-
ent options and their subsequent probabilities rely on explicit
information (decision under risk). The BART involves a variable
number of choices in a context of increasing risk. We were the
first to report reduced performance on decision-making under
ambiguity (IGT) in drug-free patients with NC in contrast to nor-
mal decision-making under explicit conditions (GDT) (Bayard
et al., 2011a). In our work, patients with NC made disadvanta-
geous choices involving immediate high reward (monetary gain)
whereas future high punishment (monetary loss) had little influ-
ence. Our results were further confirmed in a modest sample size
of drug-naïve and medicated patients with NC without statisti-
cal power to compare patients taking or not stimulants (Delazer
et al., 2011).
Most of psychostimulants (modafinil, methylphenidate, and
amphetamines) used to manage sleepiness in NC increase wake-
fulness potentially through inhibition of the dopamine trans-
porter and augmentation of cortical and caudate dopamine
concentrations (Wisor and Eriksson, 2005). Recently, two case
reports described the association between modafinil, patholog-
ical gambling, and severe mania in the context of NC (Tarrant
et al., 2010; Crosby et al., 2011). Given that background, we
were interested in comparing addiction, pathological gambling
and risk-taking on the IGT and the GDT in drug-free, stimulant-
medicated patients with NC, and controls. We demonstrated on
a large clinical sample that patients with NC either drug-free or
medicated with psychostimulant selected more disadvantageous
choices under ambiguous conditions (IGT) than controls, with-
out differences between patients treated or not (Bayard et al.,
in press). Furthermore, we found that psychostimulants did not
increase risky-taking behavior on the GDT, substance addiction
and pathological gambling occurrence. In addition to the lack
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of relationship between the IGT performances and many char-
acteristics of NC, our recent results favor a direct impact of the
hypocretin deficiency in triggering the risky-taking behaviors in
NC. Finally, another study using the BART reported normal risk-
taking behavior in patients with NC or with narcolepsy without
cataplexy, but patients with cataplexy were more impulsive and
more prone to binge eating (Delazer et al., 2011; Dimitrova et al.,
2011).
Impulsivity and sensation-seeking are two behavioral dimen-
sions being closely related to the concepts of decision-making and
rewarding (Zermatten et al., 2005; Bayard et al., 2011b; Dretsch
and Tipples, 2011). To the best of our knowledge, only few stud-
ies focused on self-reported impulsivity and sensation-seeking
behaviors in NC but with non-robust results. We have explored
the four facets of impulsivity proposed by Whiteside and Lynam
(2001) using the UPPS Impulsive Behavior Scale in patients with
NC. The first dimension of the scale, urgency, refers to diffi-
culty resisting strong impulses driven by negative affect. The
second dimension, premeditation, is characterized by an inabil-
ity to consider the potential consequences of one’s behavior. The
third dimension, perseverance, refers to the lack of ability to stay
on task while experiencing boredom. Finally, sensation-seeking
refers to an individual’s need for excitement and stimulation. In
a first study, we found that drug-naïve patients with NC showed
lack of perseverance on the UPPS (Bayard et al., 2011a). However,
on a larger sample of drug-free and medicated patients matched
to healthy controls, we were unable to reproduce this observa-
tion (Bayard et al., in press). Regarding the discrepancies observed
on the UPPS, sensitivity analyses indicated no significant differ-
ence between patient’s characteristics from our first study (Bayard
et al., 2011a) compared to those from our second study (Bayard
et al., in press). Discrepancy between both studies may be due
to type I error risk due to the small population of subjects
included in the previous study. On the Eysenck Impulsiveness
Scale, Dimitrova and colleagues found that patients with NC
scored higher than controls (10 vs. 0%), while there was a trend
for the patients with narcolepsy without cataplexy (6.7%) to score
higher than controls (Dimitrova et al., 2011). In addition, sim-
ilar scores on the five dimensions of the Zuckerman Sensation
Scale (i.e., general sensation seeking, thrill and adventure seeking,
experience seeking, disinhibition, and boredom susceptibility)
were found among patients with narcolepsy with and without
cataplexy and controls.
In conclusion, patients with NC either drug-free or medicated
with psychostimulant had reduced performances in decision-
making under ambiguous condition compared to controls, with-
out differences between patients treated or not. The performance
discrepancies found between decision-making under ambigu-
ous (IGT) but not risky conditions (GDT, BART) may be
linked to different cerebral networks involved under these con-
ditions. In fact, brain lesion and neuroimaging studies have con-
firmed that the fronto-cortico-striatal loop is crucially involved
in decision-making under risk, whereas the limbic loop (i.e.,
orbitofrontal/ventromedial prefrontal cortex and amygdala) is
preferentially involved in reward processing under ambiguity
(Brand et al., 2007). As hypocretin neurons densely project to
these limbic reward-associated brain regions, we may suggest
that hypocretin deficiency in NC trigger abnormal performances
in decision-making under ambiguity. Finally, there is no robust
evidence for any clinically-significant association between impul-
sivity and hypocretin-deficient patients with NC.
MOOD SYMPTOMS
Hypocretins act primarily as excitatory neurotransmitters to
control monoaminergic and cholinergic neuron activities.
Hypocretin deficiency induces a cholinergic–monoaminergic
imbalance, with primary effect on vigilance as well as other func-
tions includingmood regulation. As hypocretins are also involved
in neuroendocrine functions and stress reactions through stimu-
lation of the hypothalamus–pituitary–adrenal axis (Kuru et al.,
2000), hypocretin deficiency per se may trigger mood distur-
bances and psychological alterations through diverse pathways.
One recent animal study supported the specific role of
hypocretin receptors in the modulation of depression-like behav-
ior. After genetic or pharmacologic inhibition of hypocretin
receptor signaling, the hypocretin activity balance at either Hcrtr1
or Hcrtr2 produced an antidepressant- or prodepressant-like
effect depending on the subtype activated (Scott et al., 2011).
Hcrtr1 null mice displayed a significant reduction in time immo-
bile and in latency to first bouts of immobility in the forced
swim test, consistent with reduced depression-like behavior.
Pharmacologic inhibition of hcrtr1 also produced the same pat-
tern of behavior, but without any impact on anxiety level as
shown by the results on the elevated plus maze and the light-
dark box. In contrast, hcrtr2-null mice displayed an increase in
behavioral despair but again without any effect on measures of
anxiety.
High levels of psychopathology were frequently reported in
cross-sectional studies in narcolepsy, with high rate (from 15
to 37%) of moderate to severe self-reported depressive symp-
toms (Roy, 1976; Kales et al., 1982; Krishnan et al., 1984; Mosko
et al., 1989; Vandeputte and De Weerd, 2003; Vignatelli et al.,
2004, 2011; Dodel et al., 2007; Dauvilliers et al., 2009; Bayard
et al., 2011a, 2012a). A case-control study found mood disorder
symptoms in one-third of narcolepsy patients, but with similar
frequency of formal mood disorder diagnoses (Fortuyn et al.,
2010). In contrast over half the patients had anxiety or panic
attacks, and 35% had anxiety disorders. Interestingly, in a 5-year
cohort study of patients with narcolepsy-cataplexy, mood symp-
toms remained relatively stable, with 25% of patients showing
constant moderate to severe mood symptoms across assessments
(Vignatelli et al., 2011). Our large cross-sectional narcolepsy study
found that depressive symptoms (using the BDI-II) were associ-
ated with greater EDS severity, greater alterations in physical and
mental health quality of life, as well as increased frequency of
REM sleep manifestations such as cataplexy, hypnagogic halluci-
nations, and sleep paralysis (Dauvilliers et al., 2009). In addition,
we found that anticataplectics at doses prescribed for cataplexy
management were ineffective in treating depressive symptoms.
In conclusion, a high frequency of depressive symptoms has
been systematically reported in NC, supporting the hypothesis
of an endogenous mood problem dysregulation. Nevertheless, a
“subsyndromal form of depression” would be more appropriate
to qualify the mood disorder in NC.
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ADDICTION
Drug addiction is a relapsing disorder characterized by compul-
sion to seek and take drugs with major link to dysregulation
of brain regions that mediate reward and stress. Animal studies
have undoubtedly documented the role of the hypocretinergic
system in addiction (Aston-Jones et al., 2009). Hypocretin neu-
ron activities varied in proportion to drug or food preference
and their neurotransmission is needed for reinstatement of an
extinguished preference for morphine (Harris et al., 2007) and
cocaine-seeking (Boutrel et al., 2005). Do these data from exper-
iments conducted in laboratory animals have any correlates in
humans? In seminal review papers on this topic, it is currently
stated that “. . . human narcoleptics, who have few or no orexin
neurons, rarely exhibit stimulant abuse and seeking despite the fact
that they are treated for years with stimulants . . .” (Aston-Jones
et al., 2009) or “. . . patients with narcolepsy are often treated
using addictive amphetamine-like drugs such as methylphenidate,
amphetamine and γ-hydroxybutyrate, but rarely become addicted
to these drugs . . .” (Tsujino and Sakurai, 2009). Nevertheless,
to the best of our knowledge, no data in humans have vali-
dated this clinical observation stating that hypocretin deficiency
constitutes a protective factor against the development of addic-
tion. One isolated study performed on a modest sample size
population documented that substance and alcohol abuse and
compulsive gambling were similar between patients with NC,
patients with narcolepsy without cataplexy and healthy con-
trols (Dimitrova et al., 2011). Our clinical experience revealed
that patients with NC easily stop their psychostimulant med-
ication (i.e., due to adverse effects, during pregnancy or for
research purposes) without frequent occurrence of withdrawal
symptoms in contrast to the frequent rebound of cataplexy after
stopping antidepressant anticataplectic medication. However,
similar observations were noted when stopping psychostimu-
lant in other central hypersomnia conditions characterized by
normal hypocretin activity (i.e., idiopathic hypersomnia with
and without long sleep time, and 80% of narcolepsy with-
out cataplexy). Although the behavioral pharmacological pro-
file of methylphenidate, cocaine and d-amphetamine shared
some similarities, the actual rates of abuse in animals and in
humans are much lower for methylphenidate (Kollins et al.,
2001). Altogether, we cannot conclude that the amphetamine-like
drugs used to manage sleepiness in NC have particular addictive
properties.
In conclusion, even if hypocretin deficiency that character-
ized the physiopathology of NC provides a fascinating insight
into the roles of the hypocretins in addiction development, litera-
ture is lacking of robust data to document this topic in human
narcolepsy. Understanding the function of basic brain stress
and reward systems in hypocretin-deficient patients with nar-
colepsy may provide novel targets for treatment and prevention
of addiction.
CONCLUSION AND PERSPECTIVES
The specific physiopathology of NC defined by hypocretin defi-
ciency provides a fascinating insight into the roles of hypocretin
in human behavioral regulation. Although a role for hypocre-
tin in the regulation of sleep/wakefulness state is widely rec-
ognized, other functions, not necessarily related to arousal,
have been identified. Animal studies have shown that hypocre-
tin plays an essential role in reward-seeking and addiction;
however, patients with narcolepsy-cataplexy presented risky
choices in a decision-making task under ambiguity together
with higher frequency of depressive symptoms and binge eating
disorder but without any significant association with patho-
logical impulsivity and gambling, and substance and alcohol
abuse.
Prospective larger studies are required to confirm these find-
ings in narcolepsy but also in the context of other central hyper-
somnias without hypocretin deficiency to answer the question
of the role of the hypocretin system in reward-based behav-
iors and emotional processing in humans. Further interventional
studies are also needed to explore whether management of sleepi-
ness using psychostimulant modifiedmood symptoms, gambling,
risky behaviors and addiction in central hypersomnia disorders.
Finally, the future use of non-selective hypocretin-1 and -2 ago-
nists and antagonists appears particularly promising to treat sev-
eral neuropsychiatric disorders, including narcolepsy, insomnia,
but also drug addiction.
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